372105-27-6
|
|
|
- CAS号:
- 372105-27-6
- 英文名:
- naMitecan
- 英文别名:
- ST-1968;naMitecan;1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-11-carboxaldehyde, 4-ethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-, 11-[O-(2-aminoethyl)oxime], [C(E),4S]-
- 中文名:
- 372105-27-6
- 中文别名:
- 化合物 T16268;[C(E),4S]-4-乙基-3,4,12,14-四氢-4-羟基-3,14-二氧-1H-吡喃并[3',4':6,7]吲哚并[1-2,B]喹啉-11-甲醛 11-[O-(2-氨基乙基)肟]
- CBNumber:
- CB12628184
- 分子式:
- C23H22N4O5
- 分子量:
- 434.44458
- MOL File:
- 372105-27-6.mol
|
|
|
372105-27-6化学性质
-
沸点:
-
835.2±75.0 °C(Predicted)
-
|
-
密度:
-
1.51±0.1 g/cm3(Predicted)
-
|
-
储存条件:
-
Store at -20°C
-
|
-
溶解度:
-
DMSO: 250 mg/mL (575.45 mM)
-
|
-
形态:
-
Solid
-
|
-
酸度系数(pKa):
-
11.20±0.20(Predicted)
-
|
-
颜色:
-
Light yellow to yellow
-
|
372105-27-6性质、用途与生产工艺
Namitecan 是一种 topoisomerase I 抑制剂，具有抗肿瘤活性。
Namitecan and cetuximab cooperate in inhibiting EGFR expression. Namitecan induces a dose-dependent decrease in EGFR expression in the different cell lines. ST1968 induces a comparable level of apoptosis in A431 and A431/TPT cells with IC
50
of 0.21 and 0.29 μM.
Namitecan (10 mg/kg) in combination with cetuximab (1 mg/mouse) induces synergistic antitumor effects in SCC models as a function of EGFR gene copy number. ST1968 (25 mg/kg) causes acceptable body weight loss and no toxic deaths. ST1968 produces a 100% complete response rate in the mice bearing the A431 tumor, and retains a relevant activity in the topotecan-resistant tumor.
372105-27-6
上下游产品信息
上游原料
下游产品
| 更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
|---|
| 2024/04/30 | HY-14821 | 372105-27-6
Namitecan | 372105-27-6 | 1mg | 2450元 |
| 2024/04/30 | HY-14821 | 372105-27-6
Namitecan | 372105-27-6 | 10mM * 1mLin DMSO | 4780元 |
372105-27-6, 372105-27-6 相关搜索:
- 化合物 T16268
- [C(E),4S]-4-乙基-3,4,12,14-四氢-4-羟基-3,14-二氧-1H-吡喃并[3',4':6,7]吲哚并[1-2,B]喹啉-11-甲醛 11-[O-(2-氨基乙基)肟]
- 372105-27-6
- 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-11-carboxaldehyde, 4-ethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-, 11-[O-(2-aminoethyl)oxime], [C(E),4S]-
- ST-1968
- naMitecan